|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
146,000,000 |
Market
Cap: |
16.87(B) |
Last
Volume: |
1,904,666 |
Avg
Vol: |
1,333,207 |
52
Week Range: |
$92.79 - $212.65 |
|
Level
I Sector: |
Information Technology |
Level
II Sector: |
Electronics |
Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : 11.4 |
Insider 6 Months : 11.4 |
Insider 3/6 Months : 23.2 |
|
Guru Rank Number : 691 |
Guru Rank Value : 2.3 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
7,330 |
7,330 |
7,330 |
7,330 |
Total Buy Value |
$991,672 |
$991,672 |
$991,672 |
$991,672 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
0 |
0 |
6,815 |
22,740 |
Total Sell Value |
$0 |
$0 |
$1,357,080 |
$4,648,975 |
Total People Sold |
0 |
0 |
2 |
3 |
Total Sell Transactions |
0 |
0 |
5 |
17 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ostadan Omead |
SVP Mktg, Prod & Strat Plan |
|
2020-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,744 |
17,155 |
|
- |
|
Mcginnis Karen K |
VP, Chief Accounting Officer |
|
2020-02-11 |
4 |
D |
$296.00 |
$158,656 |
D/D |
(536) |
4,206 |
|
- |
|
Mcginnis Karen K |
VP, Chief Accounting Officer |
|
2020-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,001 |
4,742 |
|
- |
|
Mcginnis Karen K |
VP, Chief Accounting Officer |
|
2020-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
501 |
3,741 |
|
- |
|
Tousi Susan H |
SVP Product Development |
|
2020-02-11 |
4 |
D |
$296.00 |
$2,048,320 |
D/D |
(6,920) |
48,654 |
|
- |
|
Tousi Susan H |
SVP Product Development |
|
2020-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,969 |
55,574 |
|
- |
|
Tousi Susan H |
SVP Product Development |
|
2020-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
4,985 |
45,605 |
|
- |
|
Ronaghi Mostafa |
SVP & CTO |
|
2020-02-11 |
4 |
D |
$296.00 |
$2,434,896 |
D/D |
(8,226) |
86,506 |
|
- |
|
Ronaghi Mostafa |
SVP & CTO |
|
2020-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,728 |
94,732 |
|
- |
|
Ronaghi Mostafa |
SVP & CTO |
|
2020-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,864 |
83,004 |
|
- |
|
Desouza Francis A |
President and CEO |
|
2020-02-11 |
4 |
D |
$296.00 |
$7,595,064 |
D/D |
(25,659) |
93,158 |
|
- |
|
Desouza Francis A |
President and CEO |
|
2020-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,184 |
118,817 |
|
- |
|
Desouza Francis A |
President and CEO |
|
2020-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
17,592 |
83,633 |
|
- |
|
Dadswell Charles |
SVP & General Counsel |
|
2020-02-11 |
4 |
D |
$296.00 |
$1,531,504 |
D/D |
(5,174) |
11,769 |
|
- |
|
Dadswell Charles |
SVP & General Counsel |
|
2020-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,624 |
16,943 |
|
- |
|
Dadswell Charles |
SVP & General Counsel |
|
2020-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,812 |
9,319 |
|
- |
|
Mcginnis Karen K |
VP, Chief Accounting Officer |
|
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
999 |
3,240 |
|
- |
|
Goswami Joydeep |
SVP Corp Business Development |
|
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,665 |
2,992 |
|
- |
|
Hoyt Aimee L |
SVP, Chief People Officer |
|
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,873 |
4,106 |
|
- |
|
Desouza Francis A |
President and CEO |
|
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
8,324 |
66,041 |
|
- |
|
Ostadan Omead |
SVP Mktg, Prod & Strat Plan |
|
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,498 |
10,411 |
|
- |
|
Febbo Phillip G. |
SVP Chief Medical Officer |
|
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,249 |
2,755 |
|
- |
|
Dadswell Charles |
SVP & General Counsel |
|
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,873 |
5,507 |
|
- |
|
Tousi Susan H |
SVP Product Development |
|
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,081 |
40,620 |
|
- |
|
Ronaghi Mostafa |
SVP & CTO |
|
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,665 |
77,140 |
|
- |
|
3455 Records found
|
|
Page 17 of 139 |
|
|